Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to $140.0 million.

  • Standard Biotools' Total Liabilities fell 2717.34% to $140.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.0 million, marking a year-over-year decrease of 2717.34%. This contributed to the annual value of $140.6 million for FY2024, which is 1203.64% down from last year.
  • As of Q3 2025, Standard Biotools' Total Liabilities stood at $140.0 million, which was down 2717.34% from $132.4 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Total Liabilities ranged from a high of $249.8 million in Q1 2022 and a low of $125.0 million during Q1 2025
  • Moreover, its 5-year median value for Total Liabilities was $166.4 million (2022), whereas its average is $170.2 million.
  • As far as peak fluctuations go, Standard Biotools' Total Liabilities skyrocketed by 3707.07% in 2022, and later tumbled by 3760.85% in 2025.
  • Over the past 5 years, Standard Biotools' Total Liabilities (Quarter) stood at $180.6 million in 2021, then decreased by 11.13% to $160.5 million in 2022, then dropped by 0.41% to $159.9 million in 2023, then fell by 12.04% to $140.6 million in 2024, then dropped by 0.46% to $140.0 million in 2025.
  • Its last three reported values are $140.0 million in Q3 2025, $132.4 million for Q2 2025, and $125.0 million during Q1 2025.